Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Biostage, Inc. stock logo
BSTG
Biostage
$4.45
$4.45
$4.45
$4.45
$61.78M-1.021,847 shsN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
$1.61
-1.2%
$1.50
$0.68
$4.58
$48.36M1.64131,227 shs96,293 shs
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$0.18
$4.22
$0.66
$10.77
$1.75M-1.237.68 million shs240,899 shs
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Biostage, Inc. stock logo
BSTG
Biostage
0.00%0.00%0.00%0.00%-25.34%
DarioHealth Corp. stock logo
DRIO
DarioHealth
+1.87%+14.79%+20.74%-12.83%-55.83%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
+4.06%+4.88%+3.45%-10.49%-92.84%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/AN/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
1.4079 of 5 stars
3.51.00.00.01.30.81.3
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
3.00
Buy$5.37233.33% Upside
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/A

Current Analyst Ratings

Latest OBLN, BSTG, and DRIO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/1/2024
DarioHealth Corp. stock logo
DRIO
DarioHealth
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$4.00
(Data available from 5/8/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/A($0.26) per shareN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
$20.35M2.35N/AN/A$2.14 per share0.75
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
$1.59M1.10N/AN/A$0.60 per share0.29

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Biostage, Inc. stock logo
BSTG
Biostage
-$6.07M-$0.58N/AN/AN/AN/A-174.43%N/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$59.43M-$1.03N/AN/AN/A-165.96%-48.84%-31.56%5/15/2024 (Confirmed)
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
-$12.33MN/AN/AN/A-776.76%-161.38%-83.58%N/A

Latest OBLN, BSTG, and DRIO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2024N/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$0.59N/A+$0.59N/AN/AN/A  
3/28/2024Q4 2023
DarioHealth Corp. stock logo
DRIO
DarioHealth
-$0.54-$0.41+$0.13-$0.41$3.57 million$3.62 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Biostage, Inc. stock logo
BSTG
Biostage
N/AN/AN/AN/AN/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
N/AN/AN/AN/AN/A
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Biostage, Inc. stock logo
BSTG
Biostage
N/A
2.73
2.73
DarioHealth Corp. stock logo
DRIO
DarioHealth
0.42
3.79
3.38
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
N/A
1.86
1.86

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Biostage, Inc. stock logo
BSTG
Biostage
N/A
DarioHealth Corp. stock logo
DRIO
DarioHealth
33.39%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
18.64%

Insider Ownership

CompanyInsider Ownership
Biostage, Inc. stock logo
BSTG
Biostage
15.30%
DarioHealth Corp. stock logo
DRIO
DarioHealth
10.10%
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
8.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Biostage, Inc. stock logo
BSTG
Biostage
713.88 million11.76 millionNot Optionable
DarioHealth Corp. stock logo
DRIO
DarioHealth
27629.67 million26.67 millionOptionable
Obalon Therapeutics, Inc. stock logo
OBLN
Obalon Therapeutics
210.02 millionN/ANot Optionable

OBLN, BSTG, and DRIO Headlines

SourceHeadline
Obalon Therapeutics, Inc.Obalon Therapeutics, Inc.
thestreet.com - February 25 at 12:23 PM
Spero Therapeutics Inc.Spero Therapeutics Inc.
wsj.com - February 6 at 3:31 PM
Intragastric Balloon Market Growth and Forecast till 2031Intragastric Balloon Market Growth and Forecast till 2031
marketwatch.com - March 28 at 11:39 PM
Intragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 PagesIntragastric Balloons Market to Grow with a Significant CAGR During the forecast period 2022-2028| Exclusive Report Spread Across 149 Pages
marketwatch.com - August 17 at 9:10 PM
Renovare Environmental Inc (RENO)Renovare Environmental Inc (RENO)
investing.com - January 5 at 8:30 AM
Understanding Atara Biotherapeuticss Unusual Options ActivityUnderstanding Atara Biotherapeutics's Unusual Options Activity
benzinga.com - August 10 at 11:04 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Biostage logo

Biostage

OTCMKTS:BSTG
Biostage, Inc., a biotechnology company, offers products to cure patients of cancers, injuries, and birth defects of the gastro-intestinal tract and the airways. The company's pipeline includes organ-regeneration technology for the repair or replacement of diseased or damaged organs, as well as product candidates to treat cancer, injury, and birth defects of the bronchus. Its lead product candidate is Biostage Esophageal Implant for the treatment of severe esophageal disease. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2009 and is headquartered in Holliston, Massachusetts.
DarioHealth logo

DarioHealth

NASDAQ:DRIO
DarioHealth Corp. operates as a digital health company in the United States, Canada, the European Union, Australia, and New Zealand. Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health. The company offers Dario Evolve, a metabolic solution to address metabolic health needs, such diabetes, pre-diabetes, hypertension, and weight management; Dario Move, which address most common musculoskeletal conditions; Dario Elevate, a behavioral health solution that optimizes access to evidence-based care; and Dario One, a full suite of chronic condition management solution; and Dario blood glucose monitoring systems. It also provides native devices, such as glucose meter, blood pressure cuff, digital scale, and biofeedback sensor device, as well as live coaching services. The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.
Obalon Therapeutics logo

Obalon Therapeutics

NASDAQ:OBLN
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity. The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity. Its Obalon Balloon System comprises of a swallowable capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas. Obalon Therapeutics, Inc. was incorporated in 2008 and is headquartered in Carlsbad, California.